GT Biopharma Inc
GTBP
NASDAQ
Biotechnology
$0.30
USD
0.00 (-0.47%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $13.19M
Volume 649.6K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-47.73M
TTM
-309.0%
YoY
Operating Cash Flow
$-13.18M
TTM
-20.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 0.8 | 1.2 | 2.7 | 4.2 | 2.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 1.9 | 1.5 | 3.4 | 5.6 | 2.8 |
Operating Income | -1.9 | -1.5 | -3.4 | -5.6 | -2.8 |
EBITDA | -1.9 | -1.5 | -3.4 | -5.6 | -2.8 |
Other Income / Expense | 1.1 | -28.7 | 11.6 | -17.3 | 0.0 |
Total Other Income / Expense | 1.2 | -28.7 | 11.7 | -17.4 | 0.0 |
Income Before Income Taxes | -0.8 | -30.2 | 8.3 | -23.0 | -2.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -0.8 | -30.2 | 8.3 | -23.0 | -2.8 |
Consolidated Net Income / Loss | -0.8 | -30.2 | 8.3 | -23.0 | -2.8 |
Net Income Attributable to Common Shareholders | -0.8 | -30.3 | 4.1 | -28.9 | -3.4 |
Basic EPS | -$0.33 | -$10.92 | $1.04 | -$2.50 | -$0.11 |
Diluted EPS | -$0.33 | -$10.92 | $1.04 | -$2.50 | -$0.11 |
Basic Shares Outstanding | 2.3M | 2.8M | 3.9M | 11.6M | 30.3M |
Diluted Shares Outstanding | 2.3M | 2.8M | 3.9M | 11.6M | 30.3M |